Vascular measurements correlate with estrogen receptor status

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Lloyd, Mark C ^a,c   Alfarouk, Khalid O ^a,b   Verduzco, Daniel ^a   Bui, Marilyn M ^a   Gillies, Robert J ^a   Ibrahim, Muntaser E ^b   Brown, Joel S ^c   Gatenby, Robert A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Breast cancer; Darwinian dynamics; ER; Hecrosis; Phenotypic prediction; Selection; Vasculature

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADAPTATION; ALGORITHM; ARTICLE; BLOOD FLOW; BREAST CANCER; CANCER GRADING; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE NECROSIS; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC SELECTION; GENETICS; METABOLISM; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; SELECTION, GENETIC; TUMOR MICROENVIRONMENT;

EID: 84899906671     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-279     Document Type: Article

References (33)

1. Thomas C, Gustafsson J. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011, 11(8):597-608. 10.1038/nrc3093, 21779010.
2. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann N Y Acad Sci 1995, 768:91-100. 10.1111/j.1749-6632.1995.tb12113.x, 8526389.
3. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen?. Endocr Rev 2000, 21(1):40-54.
4. Devanesan P, Santen RJ, Bocchinfuso WP, Korach KS, Rogan EG, Cavalieri E. Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-alpha knock-out (ERKO)/Wnt-1 mice: implications for initiation of mammary tumors. Carcinogenesis 2001, 22(9):1573-1576. 10.1093/carcin/22.9.1573, 11532882.
5. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006, 102(1-5):89-96. 1832080, 17113977.
6. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. NEJM 2006, 354(3):270-282. 10.1056/NEJMra050776, 16421368.
7. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology; College of American Pathologists. (2010). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010, 134(7):e48-e72.
8. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007, 25(25):3846-3852. 10.1200/JCO.2007.11.9453, 17679725.
9. Endo Y, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Iwasa M, Kobayashi S, Fujii Y, Yamashita H. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol 2011, 16(5):512-518. 10.1007/s10147-011-0215-5, 21431343.
10. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 2007, 211(3):286-295. 10.1002/path.2112, 17154249.
11. Li JQ, Xu BJ, Shakhtour B, Deane N, Merchant N, Heslin MJ, Washington K, Coffey RJ, Beauchamp RD, Shyr Y, Billheimer D. Variability of in situ proteomic profiling and implications for study design in colorectal tumors. Int J Oncol 2007, 31(1):103-111.
12. Iwasa Y, Michor F. Evolutionary dynamics of intratumor heterogeneity. PLoS One 2011, 6(3):e17866. 10.1371/journal.pone.0017866, 3068148, 21479218.
13. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892. 10.1056/NEJMoa1113205, 22397650.
14. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012, 72(19):4875-4882. 10.1158/0008-5472.CAN-12-2217, 3712191, 23002210.
15. Alfarouk KO, Ibrahim ME, Gatenby RA, Brown JS. Riparian ecosystems in human cancers. Evol Appl 2013, 6(1):46-53. 10.1111/eva.12015, 3567470, 23396634.
16. Pinzone JJ, Stevenson H, Strobl JS, Berg PE. Molecular and cellular determinants of estrogen receptor α expression. Mol Cell Biol 2004, 24(11):4605-4612. 10.1128/MCB.24.11.4605-4612.2004, 416410, 15143157.
17. Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor α in ZR-75 breast cancer cells. Mol Endocrinol 2002, 16(10):2231-2242. 10.1210/me.2001-0347, 12351689.
18. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyakemail K. " Molecular definition of breast tumor heterogeneity" . Cancer Cell 2007, 11(3):259-273. 10.1016/j.ccr.2007.01.013, 17349583.
19. Jiang Y, Pjesivac J, Freyer J. A Cellular Model for Avascular Tumor Growth. Abstracts of ICSB 2002, the 3rd International Conference on System Biology-" The Logic of Life" 2002, 123-124. Stockholm, Sweden: Karolinska Institutet, http://www.ki.se/icsb2002/abstracts.html.
20. Qureshi A, Pervez S. Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers. J Pak Med Assoc 2010, 60(5):350-353.
21. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17(5):1474-1474.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991, 19(5):403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
23. Kunz P, Hoffend J, Altmann A, Dimitrakopoulou-Strauss A, Koczan D, Eisenhut M, Bonaterra GA, Dengler TJ, Mier W, Haberkorn U, Kinscherf R. Angiopoietin-2 overexpression in morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes. J Nucl Med 2006, 47(9):1515-1524.
24. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012, 72(2):402-407. 10.1158/0008-5472.CAN-11-2464, 3261301, 22127927.
25. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996, 6:10-21. 10.1016/S1053-4296(96)80032-4, 10717158.
26. Bernards R. Cancer: cues for migration. Nature 2003, 425(6955):247-248. 10.1038/425247a, 13679899.
27. Clavo B, Robaina F, Catalá L, Pérez JL, Lloret M, Caramés MA, Morera J, López L, Suárez G, Macías D, Rivero J, Hernández MA. Effect of cervical spinal cord stimulation on regional blood flow and oxygenation in advanced head and neck tumours. Ann Oncol 2004, 15(5):802-807. 10.1093/annonc/mdh189, 15111351.
28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62. 10.1126/science.1104819, 15637262.
29. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007, 8(8):R157. 10.1186/gb-2007-8-8-r157, 2374988, 17683518.
30. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124(7):966-978.
31. Vaupel P. Hypoxia in neoplastic tissue. Microvasc Res 1977, 13(3):399-408. 10.1016/0026-2862(77)90106-6, 327212.
32. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992, 23(7):755-761. 10.1016/0046-8177(92)90344-3, 1377162.
33. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999, 79(5/6):991. 2362675, 10070902.